Welcome to our dedicated page for Biotricity news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on Biotricity stock.
Biotricity Inc. (BTCY) delivers innovative medical technology solutions focused on AI-powered cardiac monitoring and chronic disease management. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in remote patient care.
Access timely press releases covering regulatory milestones, clinical study results, and strategic partnerships with healthcare institutions. Stay informed about product developments like the Bioflux cardiac monitoring system and consumer-focused Biolife platform, which combine medical-grade accuracy with AI-driven analytics.
Our curated news collection features earnings reports, technology patent announcements, and market expansion updates. Bookmark this page for verified information about BTCY’s progress in transforming cardiac care through connected health solutions.
Biotricity Inc. (NASDAQ:BTCY) announced a Phase I study on its innovative AI system, Bioflux-AI, for real-time monitoring of stroke risk in Chronic Kidney Disease (CKD) patients. Sponsored by the NIH, the study aims to address the significantly higher stroke risk in CKD patients, which is 5 to 30 times greater than the general population. The technology combines mobile cardiac telemetry with AI algorithms to improve predictive accuracy, targeting a reduction in mortality rates and healthcare costs associated with CKD treatment. Biotricity aims to enhance personalized care through this initiative.
Biotricity (NASDAQ: BTCY) reported its fiscal 2023 first-quarter financial results on August 15, 2022, revealing a revenue of $2.1 million and a gross profit of $1.2 million, maintaining a gross margin of 60%. The company experienced a net loss of $5 million, or $0.098 per share. CEO Dr. Waqaas Al-Siddiq highlighted the successful rollout of new product lines, including Biotres and Bioheart, following FDA clearance. The expansion aims to enhance the Biotricity ecosystem and target hospital networks.
Biotricity Inc. (BTCY) reported significant growth in its fiscal 2022 results, achieving a 126% increase in annual revenue to $7.7 million. The fourth quarter saw an 81% rise in revenue, totaling $2.15 million, with gross profit margins enhancing to 67%. Despite robust revenue growth, the company recorded a net loss of $30.2 million for FY22. Biotricity launched new products including Biotres and Bioheart, expanding its market to approximately $25 billion. The company holds $12 million in cash and has enhanced its industry profile by being listed on NASDAQ.
Biotricity Inc. (NASDAQ:BTCY) announced its expected inclusion in the Russell Microcap® Index effective June 27, 2022. This membership, determined by market capitalization and style attributes, is significant for the company as Russell indexes are widely utilized by investment managers and institutional investors, with approximately $12 trillion in assets benchmarked against them. The inclusion also means Biotricity will be part of both growth and value style indexes for one year, enhancing its visibility in the financial markets.
Biotricity Inc. (NASDAQ:BTCY) will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The Company’s Founder & CEO, Dr. Waqaas Al-Siddiq, is scheduled to speak on May 24th at 3:30 PM ET at Splash 16. He will discuss the Company’s business developments and future objectives as Biotricity aims to become a comprehensive cardiac diagnostics platform. This hybrid event offers both virtual and in-person participation, emphasizing Biotricity’s commitment to innovation in healthcare.
Biotricity (NASDAQ:BTCY) reported strong strategic initiatives and growth opportunities in its recent shareholder update. The company has expanded its national sales force to cover 27 states, enhancing demonstrations of its cardiac devices. The FDA cleared its Biotres cardiac monitoring device, expanding its total addressable market (TAM) from $1B to $25B. Biotricity achieved a significant 93% YOY revenue growth to $1.93 million in Q3 2021 and raised $12 million in non-dilutive debt financing. As COVID-19 recedes, the company anticipates increased sales opportunities in 2022.
Biotricity (NASDAQ:BTCY) announced pre-order sales of its FDA-cleared wireless wearable device, Biotres, designed for early detection of cardiac arrhythmias. Official commercial sales will launch in April 2022, following strong pre-order demand from physicians and individual users. Biotres, a three-lead device, enhances ECG monitoring efficiency compared to traditional Holter monitors, positioning the company to tap into a $5.7 billion market. Biotricity plans to expand its product line throughout 2022, aiming to increase revenue and customer reach.
Biotricity, Inc. (NASDAQ:BTCY) announced its participation in the 34th Annual Roth Conference from March 13-15, 2022, in Dana Point, California. This follows a strong fiscal third quarter, reporting a 93% year-over-year revenue growth and its highest cash position. The company is now taking preorders for Biotres, a new FDA-cleared wireless cardiac monitoring device aimed at the $5.7 billion market for cardiac arrhythmia monitoring. The device enhances long-term ECG data collection, expected to ship starting April 1, 2022.
Biotricity (NASDAQ:BTCY) has announced the commencement of pre-orders for its new Biotres device, a three-lead ECG monitoring system aimed at early detection of cardiac arrhythmias. Following recent FDA clearance, pre-orders started on February 23, 2022, with shipping scheduled for April 1, 2022. The Biotres device aims to disrupt the existing cardiac monitoring market, valued at approximately $5.7 billion, by providing continuous ECG data and remote uploading capabilities, enhancing diagnostic speed and efficiency.
FAQ
What is the current stock price of Biotricity (BTCY)?
What is the market cap of Biotricity (BTCY)?
